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 ABSTRACT 
Positron emission tomography (PET) is a nuclear imaging technique using a multidisciplinary 
approach to functionally visualize processes in the brain or other living tissue. It is capable to 
determine the pharmacokinetic and pharmacodynamic properties of a molecule in the CNS, 
with a low risk of side effects on the subject. This is executed through injection of a 
radioactively labeled substance into the subject and detection of released gamma photons 
after radioactive decay of the molecule in the target organ or tissue. Based on these 
detections, it is possible to reconstruct the distribution of radioligand in the living tissue into 
an image representing the physiology of the subject.  
The present thesis focuses on the methodological development of PET imaging in small 
animal research and on the support for connecting basic research to human health-related 
clinical applications in neuroscience. The work underlying this thesis work is divided into 
three sections. Section 1 consists of the validation of a new PET/MRI small animal imaging 
system. Since the combination of an MRI magnet with a conventional PET ring could 
influence the performance of PET measurements, a combined system should be implemented 
with special care. The results of Study I showed that the combination of PET and MRI 
components did not affect the performance of the final system and it is capable to effectively 
conduct consecutive multimodal imaging with functional images from PET and anatomical 
information of soft tissue. After the validation of the PET system used in this thesis work for 
imaging, in Section 2 different methodological challenges are presented. Study II focuses on 
the transporter activity of the blood-brain barrier to highlight the necessity of proper animal 
model selection while designing pre-clinical PET studies, while in Study III we offer a 
solution for longitudinal [11C]PBR28 imaging with the validation of SUV as an outcome 
measure in rodents studies, where blood sampling is a difficult task. Within Section 3 a new 
animal model and a novel ligand is presented. The previously validated SUV approach from 
Study III is applied in Study IV during the longitudinal follow-up of the M2CAO stroke rat 
model to measure changes in the TSPO signal as a mark of neuroinflammation after cortical 
ischemia. In Study V a knockout animal model was used to validate the novel radioligand 
[11C]T-773, which was confirmed to bind selectively to the PDE10A enzyme and its 
distribution and uptake proves its suitability in small animal research. 
In conclusion the thesis focuses on the development of novel methodological platforms for 
small animal imaging PET with the aim to provide advancements in the field of translational 
neuroscience. 
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1 INTRODUCTION 
It is often challenging to find a direct connection between basic biomedical research and 
human health. It is therefore of crucial importance that we find appropriate ways to translate 
results, obtained in basic biomedical research, to human health care, including clinical 
diagnostic and therapeutic applications. With the help of translational research we are able to 
facilitate this connection through the refinement of our research tools, methods and animal 
models to advance results in applied sciences. The focus of the present thesis was to improve 
the available tools for translational research in neurological and psychiatric diseases. 
To conduct the presented experiments in this thesis work one should have relevant 
knowledge in the field of physics, chemistry, pharmacy, biology and medicine consequently 
it is important to emphasize that the present thesis work could have not been realized without 
the joint effort of an excellent multidisciplinary team. 
1.1 FUNCTIONAL IMAGING - PRINCIPLES OF PET 
Since the revolutionary discovery of Georg de Hevesy in the 1930s of using radioisotopes to 
monitor biological processes in the living organism, several methodologies have been 
developed to monitor the biochemical and physiological processes in the human body, 
including positron emission tomography (PET). PET is a nuclear imaging technique using a 
multidisciplinary approach to functionally visualize processes in the living tissue (in vivo). 
Due to its minimally invasive nature PET can determine the pharmacokinetic and 
pharmacodynamic properties of a drug candidate in the CNS with a low risk of side effects on 
the subject. In order to achieve this, the radiotracer is aimed to be administered in a 
microdosing manner (1, 2).  
1.1.1 Radiochemistry 
A PET examination requires a substance labelled with a positron emitting radionuclide to be 
present at the exact site of investigation. PET radioligands are synthesized in order to fulfil 
this goal. It consists of a pharmacophore responsible for target interaction and a positron 
emitting radionuclide which helps during the detection of said interaction. Without suitable 
imaging probes we wouldn’t be able to detect the patterns of target distribution, metabolism 
and pharmacokinetic mechanisms within the living tissue. 
To rationalize PET radioligand design and ideal candidate selection for CNS studies, several 
attributes of the pharmacophore have been selected as advantageous in order to achieve 
proper brain uptake, specific signal, and low background signal due to nonspecific binding or 
radiometabolites. Properties like mediocre lipophilicity, low molecular weight, high affinity 
and selectivity for the target with good clearance is generally preferred for brain studies in 
order for the pharmacophore to enter the blood-brain barrier (BBB) (3). Recent progress in 
protein chemistry suggests the possibility of proteins as future imaging probes as well (4). 
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1.1.1.1 Radionuclides  
Production of radiotracers is done through a particle accelerator (cyclotron) bombarding 
atoms to produce a wide variety of radionuclides used during the labelling process. The most 
commonly used radionuclides are unstable isotopes of atoms found in the human body 15O, 
11C, 13N or 18F. In the present thesis we have used the 11C radionuclide for our PET 
investigations, it has a short half-life (20.39 min) with 99.8% β+ decay (3, 5).  
1.1.1.2 Synthesis of radioligands 
After preparation, the radionuclide is rapidly reacted with a precursor used in large excess. 
Through purification the final product is separated from any remaining non-labelled precursor 
by HPLC to achieve high specific radioactivity and to avoid residual toxic effects. The PET 
radioligand production process is finally monitored by quality control to ensure proper purity, 
sterility and pH. The final labelled molecule is named differently depending on its target or 
use: radioligand (when it is binding to a specific target), radiotracer (when there is no specific 
target, but processes like metabolism is examined) or radiopharmacon (when a drug is 
labelled). 
1.1.2 PET data acquisition 
The most common route to introduce a radioactive tracer in vivo is through an intravenous 
(i.v.) injection. The radioligand accumulates with time in the target tissue and through decay 
it emits a positron (e+) which travels only a short distance (few millimetres, depending on the 
type of radionuclide) before losing its energy to the surrounding electron rich tissue. Through 
annihilation, the mass of an electron and the positron is converted into electromagnetic 
energy, which is released as two high-energy photons (511 keV) in a random direction 
180º±0.25 º (non-collinearity) apart (6). These high energy photons have a high chance to 
leave the body and therefore can be detected during PET measurements (Fig. 1).  
The facts that photons travel in a line, creating a so called line of response, and that each 
photons detection time can be individually recorded, make it possible to separate random 
detection events from the hundreds of thousands coincidence events per second. It is the 
reconstruction algorithm’s task to translate this enormous dataset of coincidence records into 
meaningful three-dimensional images (x, y, z spatial dimensions, 3D). 
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Figure 1. Schematic summary of radionuclide decay, positron scatter and photon detection in a PET ring. 
1.1.3 PET data reconstruction 
In order to calculate three dimensional images from the detected annihilations, many 
computational methods have been developed. Analytic methods like filtered back-projection 
and Fourier reconstruction has been extensively used for quantitative PET image 
reconstruction. These methods are based on the inherent assumption that the data is devoid of 
statistical noise, therefore currently used iterative methods which are counting for 
uncertainties of PET data (positron decay process, random events, hardware related etc.) by 
including data statistics in their modelling are proven to be more advantageous, albeit more 
computation heavy (7). 
In this thesis work we have used the maximum likelihood-expectation maximization 
(MLEM) algorithm (8). Depending on the radioligand, typical PET measurements are 
ranging from 20 to 120 min. During this time interval the detection is continuous and the data 
set can be reconstructed into several timeframes (3D image segments) with different frame 
length to generate a dynamic PET image for analysis. After reconstruction the dynamic four-
dimensional PET image (x, y, z spatial dimensions and time as fourth dimension, 4D) is 
representing the concentration of the radioligand in the field of view (FOV) as a function of 
time quantitatively.  
1.1.4 Region of interest analysis 
The reconstructed 4D PET images are used to generate regional time activity curves (TAC) 
by defining a region of interest (ROI) or volume of interest (VOI) over a specified area of the 
PET image. Each 3D image represents the average tracer concentration during the time 
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period, therefore averaging each voxel's uptake value within this VOI in every frame, 
presents the changes over time in the uptake of radioligand. Standard method of VOI 
delineation is done manually either directly on the PET image or on a reference anatomical 
image from the same animal. Depending on the amount and complexity of VOIs this may 
require an extensive amount of labour in case of each subject, with a high possible variability 
even with reference images available. Consequently, different template based methods have 
been developed requiring either linear or non-linear coregistration of PET to a reference 
space with premade VOI templates. 
1.1.5 Quantification of radioligand receptor binding 
To gain fully quantitative information on receptor binding, mathematical modelling of the 
regional TAC’s kinetic properties is required. Several models have been created to describe 
the relationship between input to the tissue (radioligand concentration in plasma) and the 
induced response in said tissue (radioligand concentration in the target region) to define the 
behaviour of radioligands in the body. While the uptake of a ligand depends on its interaction 
with every organ, tissue, cell or molecule, each model incorporates assumptions and 
simplifications to reduce the parameters needed to be calculated. 
After administration to the body, most radioligands leave the site of administration to enter a 
central compartment (like blood or plasma), from which it is exchanged with peripheral 
compartments (brain tissue) or eliminated through metabolism or excretion. This movement 
of radioligand from one compartment to another can be described by transfer rate constants 
and therefore in each compartment, characterized by its own volume, the radioligand 
concentrations are proportional to the amount of available tracer. For modelling purposes a 
compartment might include several organs or tissues if they behave uniformly. The 
multicompartmental model assumes homogenous radioligand concentration in the separate 
compartments where different parameters can be estimated through fitting the data (Fig. 2).  
In order to fit the data several methods can be used, e.g. kinetic, equilibrium and graphical 
analysis, but within this thesis work only kinetic and graphical analyses were applied. 
The two main outcome measures in quantification of receptor binding are total distribution 
volume (VT) and binding potential (BP). VT is the amount of plasma required to account for 
the amount of radioligand in 1 cm3 of tissue, and therefore it is calculated as a ratio between 
the total tracer concentration in tissue and in plasma at equilibrium. Binding potential is 
defined as the ratio between receptor density (Bmax) and the equilibrium dissociation constant 
(KD). It aims to quantify the equilibrium concentration of specific binding in the target region 
as a ratio to some other reference concentration, like plasma (BPP) or non-displaceable 
radioligand in tissue (BPND) (9). 
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Figure 2. Schematic graph of compartmental models (2-TCM, 3-TCM and reference tissue modelling) used 
during kinetic analysis in brain PET studies. C represents the concentration of radioligand in the following 
compartments: CS – specifically bound, CFT – free in tissue, CNS – non-specifically bound, CND – non-
displaceable, CP – plasma. K1, k2, k3, k4, k5, k6, K’1 and k’2 are kinetic rate constants between the different 
compartments.  
1.1.5.1 Three- and Two-tissue compartment model 
The data measured in a dynamic PET measurement is the sum of all compartments 
interaction. One of the most basic model, the three-tissue compartment model (3-TCM) aims 
to distinguish the different forms of tracer in tissue and ends up with a model that contains six 
unknown parameters, K1 to k6. The two-tissue compartment model (2-TCM) is a simplified 
version of the 3-TCM to reduce the large number of model parameters required to be 
estimated, which often would increase the variance of the resulting parameters and tends to 
be too high for reliable interpretation. In order to reduce the parameters in the 2-TCM, free 
and non-specifically bound tracer concentration is treated as a single compartment CND (non-
displaceable concentration) under the assumption that the exchange between CFT (free 
concentration in tissue) and CNS (non-specifically bound concentration) is significantly faster 
than the exchange between CFT and CS (specifically bound concentration) (Fig. 2). 
1.1.5.2 Logan graphical analysis 
The Logan plot is a graphical analysis technique developed for reversible receptor systems to 
estimate VT. The measured TAC in the target region is plotted against the measured and 
integrated plasma activity (10). It fits a linear curve instead of using iterative curve fitting 
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methods, and therefore it is much less demanding computationally. The Logan plot will reach 
a straight line after sufficient equilibration time and the slope represents the total distribution 
volume VT (11). Due to the required blood sampling to estimate the input activity to the tissue 
through compartment CP, the Logan plot is often referred to as invasive Logan plot. 
1.1.5.3 Simplified reference tissue model 
In order to estimate VT with 2-TCM or Logan plot the radioactivity concentration in plasma is 
required to be measured. Due to the invasiveness of an arterial blood measurement, 
estimation of radioligand binding within the tissue can be helpful and preferred in cases 
where a reference region is available. The main requirement for a proper reference region is 
to be devoid of the target and therefore no specific binding is present and could be described 
by the C’ND compartment only.  
The simplified reference tissue model (SRTM) is a further development of the 4 parameter 
reference tissue model developed by Lammertsma et al. (12). It reduces the number of fitted 
parameters from four to three by introducing two additional assumptions: CND = C’ND, 
meaning that the distribution volume of non-displaceable bound radioligand is the same in 
the target region and in the reference region; and that the reference tissue can be fitted by a 1-
tissue compartment model. Due to these modifications the model calculates only three 
parameters R1, k2 and BPND, using nonlinear regression techniques with increased 
convergence rate and stability versus the 4 parameter reference tissue model. In this model R1 
is the ratio between K1 and K’1 while BPND is the outcome parameter (13). 
1.2 ANATOMICAL IMAGING 
The contribution of PET imaging on revealing the function of a living tissue is outstanding. It 
is not only capable to differentiate between areas of high/low receptor density, changes in 
metabolism or tissue functions in the subject, but able to follow changes longitudinally as 
well. Depending on the target, the signal in a PET image might be originating from a specific 
tissue or could be more general, with only small differences between anatomical areas of the 
body. Even though the resolution of PET is constantly improving, its inherent limitation on 
good spatial resolution and the fact that distinct regions of the body could have similar 
functions with some of the radioligands, images from a PET measurement frequently lacks 
the information for an accurate regional identification and quantification. To circumvent the 
aforementioned issues, PET imaging is usually coupled with anatomical imaging. Both 
magnetic resonance imaging (MRI) and X-ray computed tomography (commonly referred to 
as CT) is commonly coupled with PET to acquire anatomical details. With these imaging 
techniques it is possible to achieve sub-millimetre resolutions and therefore to provide 
sufficient reference information. 
1.2.1 CT 
The first modality used to provide extra anatomical information for PET was CT imaging, 
due to its high spatial resolution and already well-established use in oncology research (14). 
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During a CT measurement, an X-ray source is rotated around the subject while the X-ray 
sensor is placed opposite from the source to collect information from the body. When X-rays 
penetrate through tissue there is a certain likelihood that it will get absorbed based on electron 
density. CT produces a topographic data volume similar to PET which can be used to show 
different structures of the body differentiated based on their ability to block the projected X-
ray. CT imaging is mostly used in bone and lung investigations, but several other diagnostic 
methods are used as well, where rapid imaging coupled with high resolution is required, like 
cardiac CT. 
Besides the anatomical information, CT imaging has another important application attributed 
to similar absorption mechanisms between PET and CT. Although the X-rays have less 
energy than gamma-rays, images from CT measurements can be used as an absorption map 
for attenuation correction to account for quantification error originating from gamma photon 
absorption in PET (15). 
Despite the usefulness of CT imaging, one major drawback is that radiation load from CT 
imaging can be an issue in longitudinal studies as significant doses (0.6 Gy, 5% of LD 50) 
can be measured in mice even after one whole-body high resolution CT scan (16).  
1.2.2 MRI 
Opposed to PET and CT imaging, MRI does not use the higher energy parts of the 
electromagnetic spectrum (gamma-rays, X-rays, etc.), but applies non-ionizing low energy 
radio waves coupled with a magnetic field to create images of the subject. In CT, the required 
radiation dose for good image quality is quite significant (17), thus MRI has an advantage 
over CT in general due to decreased radiation load. 
During MRI imaging, each proton in the subject positioned within a magnetic field is excited 
by a radio frequency pulse, while this energy is lost the tissue produces a nuclear magnetic 
resonance signal (NMR) which can be detected. Gradient coils around the subject make it 
possible to modulate the main magnetic field and therefore to make the NMR signal encode 
positional information also providing the precondition for 3D volume generation. 
While the drawback of MRI imaging compared to CT is longer acquisition time, it is 
preferred over CT thanks to the increased soft tissue contrast. This parameter is exceptionally 
important in brain studies, where white and grey matter separation is the most common way 
for gaining anatomical orientation in the tissue. The different properties of MRI imaging 
provide numerous options to emphasize the different characteristics of the tissue in our 
interest. While the most common method is T1 weighted imaging where cerebrospinal fluid 
(CSF) is black, but it is similarly easy to acquire a T2 weighted image with high intensity 
signal from CSF and damaged tissue. Even though the good soft tissue contrast made MRI 
the ideal technique for investigating the anatomy of the central nervous system, it has a wide 
array of options for functional imaging like spectroscopy, blood-oxygen-level dependent 
functional MRI or diffusion weighted imaging. 
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One obstacle of MRI as a complementary imaging for PET, is that the MRI data doesn’t 
easily translate into absorption maps. MR imaging contains information about proton density 
in the tissue and not electron density, therefore it is not easily applicable as an attenuation 
map. The biggest issue is bone and air separation considering neither bone tissue nor air has 
signal in MRI due to low proton density while bone tissue shows high absorption signal in 
CT. Though it is possible to set up an automatic segmentation map based on a-priori 
knowledge, this method is mostly applicable on body parts that are rigid and have relatively 
small variations (18).  
1.3 MULTIMODAL IMAGING IN CNS RESEARCH 
Multimodal imaging systems in small animal research are combining PET with many 
different modalities like single-photon emission computed tomography (SPECT), CT or 
MRI. While PET/SPECT provides the possibility to conduct studies with multiple 
radioligands, its usefulness has been less apparent than the combination of PET/CT or 
PET/MRI.  
Combination of PET/CT has significant advantage over a standalone PET due to high 
resolution anatomical information coupled with shorter scan times and fast attenuation 
correction measurements. CT based attenuation correction has higher statistics/lower noise 
compared to traditional attenuation measured with gamma sources, but CT based attenuation 
might produce movement related artefacts. These artefacts can lead to an erroneous PET 
measurement calibration. The issue of high radiation doses from CT measurements coupled 
with the low soft-tissue contrast for anatomical mapping, created the need for PET/MRI 
imaging systems in molecular imaging investigations. 
Currently PET and CT scans are conducted consecutively and the integration of PET 
detectors inside the CT seems impossible due to the high X-ray flux. Although integration of 
a PET ring inside an MRI is fundamentally possible and during the past years serious efforts 
have been made to implement it (19, 20), it still requires further refinements. Another path 
for an integrated PET/MRI system is similar to the design of PET/CT, the two systems built 
next to each other for consecutive imaging. Within this thesis work the integration and 
application of a small animal PET ring on a 1 Tesla magnet is presented. 
1.4 DIFFERENCES BETWEEN CLINICAL AND PRE-CLINICAL IMAGING 
Largest differences between clinical and pre-clinical imaging are originating from the size of 
the subject aimed to be investigated. For small rodents like a mouse or rat, decreased PET 
ring size is not just possible, but preferable, as a small bore size results in higher sensitivity 
and resolution. Higher sensitivity is achieved by the increased size of the angle covered by an 
individual detector element resulting in larger detection solid angle, while the resolution 
increase is the direct result of reduced non-collinearity effect. Although a smaller PET ring 
has the drawback of faster decline in spatial resolution away from the centre of FOV, it 
achieves much higher resolutions in the centre compared to clinical scanners. Resolution of 
small animal imaging systems are around 1-1.5 mm full width at half maximum (FWHM), 
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while the current clinical scanners are around 3-5 mm FWHM (21, 22). The only clinical 
system that can achieve comparable resolution with pre-clinical imaging with 1.5 mm 
FWHM is the High Resolution Research Tomograph (HRRT) of CTI-Siemens, which is built 
with decreased bore size as well, primarily for brain imaging (23). As the systems used in 
small animal imaging include smaller detector elements/detector ring it significantly reduces 
the error originating from photon non-collinearity, thus modelling of positron range becomes 
a significant importance in increasing the spatial resolution. This is usually implemented in 
the reconstruction algorithm for more accurate imaging. 
Even though the achievable resolution is higher in small animal PET compared to clinical 
PET imaging solutions, we should not forget the large differences in size between humans 
and rodents. This creates a challenge for several aspects of PET imaging in small animals. 
This is especially true for brain imaging where the size of the human brain is several hundred 
times larger than in rodents. The average brain weight of a human is around 1200-1400g, 
while the average rat and mouse brain is around 2-3g and 0.3-0.5g respectively (24). The 
lower relative resolution of small animal imaging due to size differences, results in spill over 
and partial volume effects as well as it presents a challenge in application of automatic 
coregistration methods for multimodal imaging. This results in labour intensive manual 
registration of PET images to brain atlases or individual MRI images. 
The decreased body size has an additional drawback for PET quantification due to 
significantly smaller available blood pool during input curve estimation for invasive 
modelling methods. 
1.5 TARGET SYSTEMS IN PET 
One of the advantages of PET is the diversity of the different mechanisms/targets that can be 
observed by this imaging technique. Receptor-ligand interactions are the most commonly 
examined processes with PET, while blood flow measurements or different enzymatic 
reactions either intra- or extracellularly can be followed as well. This molecular imaging 
technique is capable of revealing metabolism, protein synthesis and tissue signalling or even 
the progression of some diseases over time. 
Apart from imaging the direct interaction of specific molecules and target proteins with 
radioligands, radiotracers are aimed to be used in a more passive manner. Radiotracers like 
[15O]water or [11C]butanol can be used as a tool to estimate cerebral blood flow based on 
their passive distribution within the tissue (25), while the glucose analogue [18F]FDG is a 
widely used tracer to measure glucose metabolism, as its accumulation depends mostly on the 
glucose uptake and phosphorylation activity of the tissue. The most frequent application of 
[18F]FDG is in tumour imaging, even though newer, more specific radiotracers or 
radioligands are continuously developed (26). 
Within this thesis work phosphodiesterase 10A (PDE10A) and translocator protein (TSPO) 
radioligands have been used together with a 5-hydroxytryptamine receptor 1B (5-HT1B) 
ligand to investigate BBB interaction through transporter modulation. 
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1.5.1 The blood-brain barrier 
Species differences may result in significant variations between the efficacies of the same 
drug in different species. Therefore the metabolic, pharmacokinetic and toxicological data 
obtained in small animals should be extrapolated to other species or to humans with care. 
Such differences could originate from various factors like metabolism, resulting from the 
genetic variations in drug-metabolizing enzymes, which in turn may alter pharmacokinetics, 
drug clearance, drug efficacy and safety (27). Another possible factor resulting in species 
differences is related to the differences in the transport of drug molecules either in the 
periphery, in organs such as the liver, kidney and gastrointestinal tract or in the central 
nervous system across the BBB (28–30). 
As a general consensus the BBB is perceived as a barrier consisting of neuronal and vascular 
units protecting the brain tissue from toxic substances by their unique interaction (31). In the 
brain capillaries the BBB is built up by the interaction of endothelial cells and astrocytes, 
where the integration of neuronal projections through pericytes make vasodilatation 
regulation possible as well (32) (Fig. 3). Within this specific tissue composition endothelial 
cells are separating the blood compartment from the brain tissue. Through tight junctions 
between endothelial cells and by additional mechanisms like specific transporter systems 
within the plasma membrane the endothelial cells are capable to regulate the entry of larger 
molecules. While small or lipophilic molecules might enter the brain by passive diffusion 
(33), endothelial cells are limiting the paracellular flow of larger molecules by forming tight 
junctions between their membranes. The integrity and expression of tight junction proteins 
(occludin, claudin-5) is a crucial factor which has been shown to be regulated by gut 
microbiota (34). Besides blocking paracellular flow, endothelial cells are regulating 
transcellular flow as well by intracellular elements like enzymes, and membrane transporters. 
In order to help investigations of drug delivery or intervention efficacy, different methods 
have been used for BBB disruption (osmotic, ultrasound, bradykinin administration, 
radiation) or BBB circumvention (viral mediated, carrier molecule, liposomal delivery, 
plasma membrane transporter modulation) (35). 
Transporters in the plasma membrane of endothelial cells are becoming the main interest for 
BBB transporter function modulation. Largest family of transporters are belonging to the 
adenosine triphosphate (ATP)-binding cassette (ABC) superfamily, which includes 49 genes 
divided into seven sub-families (designated ABCA–ABCG) encoding the various ABC 
transporters in the human genome (36, 37). Three ABC subfamilies (B, C, and G) contain 
ATP mediated efﬂux pumps, which are involved in metabolite and xenobiotic transport 
throughout the barrier and excretory tissues in the body (blood and testis barrier, placenta, 
lung, gastrointestinal tract, liver, kidney), inﬂuencing the pharmacokinetics of many signal 
molecules, metabolites, toxins and therapeutic drugs (38). In the brain tissue the presence of 
the following subfamilies has been shown: ABCB1, ABCC1, ABCC2, ABCC4, ABCC5, 
ABCG2 (36). 
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Figure 3. Structure of the BBB, showing the major routes for molecular transport and cell migration through the 
capillaries into brain tissue (top right), highlighting the route of carrier mediated efflux through the luminal 
endothelial membrane (left). 
Expression of ABC transporters can be different among the species. Out of the several 
present transporters from the ABC family (e.g. ABCB1, ABCC4 and ABCG2) in the rodent 
brain, the ABCB1 sub-family encoding P-glycoproteins (P-gp) is the most abundant. The 
expression of P-gp is approximately four times higher than the breast cancer resistance 
protein (BCRP (ABCG2)) and 12 times higher than multidrug resistance-associated protein 4 
(Mrp4 (ABCC4)) in the rat brain (39). This is in contrast to human tissue where BCRP 
showed higher expression (40). Differences in BBB penetration of a radioligand between 
animal models and human measurements might have the most detrimental impact on 
application of translational results and consequently on the usefulness and predictive value of 
small animal models in drug development. 
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1.5.2 Neuroinflammation 
Recent studies indicate that neuroinflammation is playing an important role in the 
pathogenesis of depression, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease 
and even multiple sclerosis (41), while being one of the main components in the 
pathophysiological process of brain damage after cerebral ischemia (42). 
Microglia is the first cell type to respond to brain damage during neuroinflammation. They 
are resident macrophages with monocytic origin and their role is to sense CNS injury, remove 
cellular debris by phagocytosis, astrogliosis regulation or even to assist in the development of 
CNS (43). As a general process, neuroinflammation occurs through the rapid activation of 
microglia cells, while astrocytes, the secondary cell types involved during brain damage, 
respond somewhat slower (44). Besides these two major cell types, inflammatory cells from 
blood and neurons as well have been connected to neuroinflammation regulation (45). 
Microglia is formed by infiltrating monocytes as amoeboid cells during the late embryonic 
and early post-natal period in the brain (46), taking up around 5% to 12% of total cell 
population within the different areas of the mouse brain (47). Resting microglia cells have 
ramified processes but after mechanical injury, ischemia or inflammatory signalling it 
becomes activated by retracting its processes, increasing the size of its soma, while elevating 
its cytokine, chemokine, and protease production to prepare for phagocytosis and scar 
formation (Fig. 4). Microglia activation has been connected to the ATP-binding purinergic 
receptor, P2X7, which proved to be necessary but not the only regulator of activation (43). In 
the microglia activation model suggested by Monif et al. the P2X7 receptor acts as a sensory 
checkpoint, where after tissue damage the adenosine triphosphate (ATP) released from 
neurons, astrocytes or from other microglia, stimulates microglia activation and proliferation 
through the formation of the P2X7R pore, while it releases various proinflammatory 
cytokines such as interleukin-1 β (IL-1β) or tumour necrosis factor α (TNFα) to enable a 
cascade of similar microglial activation resulting in neuroinflammation (43). While such 
activation normally helps to maintain tissue homeostasis and drives repair processes (45, 48), 
over-activation can end in neuronal damage and neurodegeneration (49). 
Activated microglia shows an upregulated expression of the 18 kDa TSPO protein in the 
outer mitochondrial membrane (50). This protein shows a complex role from cell growth, 
proliferation to mitochondrial respiration and apoptosis, with cholesterol metabolism being 
one of its most well studied functions. Cholesterol transport through the cytosol is mediated 
by the steroidogenic acute regulatory protein (StAR) stimulating the transport of cholesterol 
to the mitochondrial outer membrane (51). TSPO together with at least two other subunit, a 
32 kDa voltage-dependent anion channel (VDAC) and a 30 kDa adenine nucleotide carrier 
(ANC) forms a cluster of four to six molecules creating a single pore at the outer and inner 
mitochondrial membrane contact sites (52, 53). Though TSPO is wildly perceived to possess 
a major role in steroidogenesis, Bae et al. have shown evidence on TSPO’s anti-inflammatory 
activity as an adaptive response mechanism (54).  
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 Figure 4. Illustration of the microglia activation and neuroinflammation cascade during neurodegenerative 
diseases. After tissue damage, the resting microglia changes its shape to activated microglia and activates 
astrocytes as well with pro-inflammatory mediators as a response to increased level of ATP and high-mobility 
group box 1 protein (HMGB1) in tissue. Both the astrocytes and activated microglia may produce reactive 
oxygen species (ROS) and nitric oxide (NO), thereby inducing neurotoxic effects. Further activation and 
proliferation of microglia is strengthened through astrocytic production of TNFα and colony-stimulating factor 1 
(CSF1).  
While TSPO is highly expressed in damaged tissue, it is present in the healthy brain only at 
low levels (55), therefore it has been the main target as a neuroinflammation marker in PET. 
The search for a TSPO marker resulted in the development of [11C]PK11195 (56). 
Unfortunately this wildly used TSPO radioligand shows poor signal-to-noise ratio and high 
non-specific binding (57), therefore many second generation radioligand has been developed 
such as [11C]PBR28 (58, 59), [18F]FEPPA (60), [11C]DPA-713 and [11C]DPA-714 (61). For 
this thesis work we have selected the [11C]PBR28 for imaging TSPO, since it has been shown 
that it has low nonspecific binding and increased signal-to noise ratio compared to 
[11C]PK11195 (62). In 10% of the human subjects, low affinity binders of TSPO ligands have 
been identified compared to the normal high affinity binder population (63, 64), while later a 
third group has been separated as mixed affinity binders with equal distribution of low and 
high affinity binding sites within one subject (65). The aforementioned variation in binding 
affinity is due to a single nucleotide polymorphism (rs6971) resulting in one amino-acid 
change in the TSPO protein (66). 
Although the initial observation of increased TSPO in activated microglia in ischemic tissue 
suggested a selective marker for activated microglia (67, 68), lately it has also been shown in 
reactive astrocytes around the damaged tissue (69, 70). For this reason TSPO is a complex 
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cell marker of neuroinflammation, where the signal of TSPO radioligand in brain could 
originate from both glial cell types.  
1.5.3 Phosphodiesterase 10A 
The eleven member superfamily of phosphodiesterases (PDEs) consists of more than 20 PDE 
genes and more than 50 different proteins, which are mainly involved in regulation of signal 
transduction (71, 72). PDEs are the only enzymes known to degrade cyclic nucleotides, the 
secondary messenger adenosine and guanosine 3′,5′-cyclic monophosphates (cAMP, cGMP) 
by hydrolysis to produce AMP and GMP respectively (73). Most PDE families have strict 
tissue specificity, with specific distribution over the various tissues, cells or even subcellular 
compartments in brain (74). Due to this selective distribution, the brain can accurately 
regulate the responsiveness of each tissue to cyclic monophosphate signalling (75). 
In the mammalian brain, PDE10A is selectively expressed in the medium spiny neurons of 
striatum (76, 77). It is capable of hydrolysing both cAMP and cGMP, but has higher affinity 
for cAMP, therefore cGMP hydrolysis is limited by cAMP activity (72, 78). The GABA-
ergic medium spiny neurons are involved in the direct (D1) and indirect pathways (D2) of 
dopamine signalling and activation of both pathways through inhibition of PDE10A function 
results in lower extrapyramidal side effects while keeping the function of antipsychotic drugs 
(79, 80). PDE10A has been connected to several basal ganglia related disorders such as 
bipolar disorder and Parkinson's disease (81), and it is associated also with Huntington’s 
disease (HD) (82, 83). Inhibition of PDE10A is a primary interest in research related to 
treatment of schizophrenia (84), as they provide possibility to manipulate the intracellular 
signalling cascades without the side effects of traditional neurotransmitter driven approaches 
(78). 
In order to successfully visualize changes in PDE10A levels in vivo several radioligands have 
been suggested for PET imaging: [11C]papaverine (85), [18F]JNJ41510417 (86), [11C]MP-10 
(87), [18F]MNI654, [18F]MNI659 (88, 89), [18F]JNJ42259152 (90), and [11C]AMG 7980 
(91). Due to different reasons (low binding potential, short retention time in striatum, need for 
arterial input function, etc.) neither of these radioligands have proven to be optimal for 
PDE10A imaging, thus ligand optimization is still an ongoing process. 
Several PDE10A knockout mice strains have been characterized to reveal the function of 
PDE10A in behavioural studies and to help the biomarker development. Availability of 
knockout animal strains is an advantage for identifying a selective function of a gene. One of 
the earliest PDE10A-/- mice was developed on DBA1LacJ background which was later 
transferred to a C57/Bl6N background (92). Both the C57/Bl6N and DBA1LacJ background 
knockout animals show decrease in exploratory locomotor activity, learning delay during 
conditioned avoidance responding task while maintaining equivalent levels of striatal cAMP 
or cGMP compared to wild type animals. Effects on the dopaminergic system appear to be 
background-dependent and observed on C57BL6N mice only (93). 
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Another PDE10A knockout mouse model has been developed specifically as a PDE10A2 
spliceform knockout on the C57BL6 background. While PDE10A1 is the specific spliceform 
of PDE10A in the testis, PDE10A2 is selective for the medium spiny neurons in the striatum 
(78, 94). The PDE10A2-/- mouse model does not show significant decrease on locomotor 
activity, but an increase in social interest towards other mice, providing a connection between 
the effects of PDE10A2 on cAMP signalling and social interaction (94).  
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2 AIMS 
The overall aim of the present thesis was to facilitate improvements and to develop novel 
methodological platforms for small animal imaging PET. The specific aims were the 
following: 
 To validate a multimodal imaging system specifically designed for rodent and small 
animal imaging. 
 To present the importance of animal model selection in PET translational research. 
 To offer quantification method for the neuroinflammation marker [11C]PBR28 in a 
longitudinal setup. 
 To validate a new stroke animal model for small animal research. 
 To validate a novel radioligand for PDE10A imaging.
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3 MATERIALS AND METHODS 
The present chapter is a summary of the general methods used during this thesis work.  
3.1 ANIMALS 
All animals were acquired from Charles River Laboratories (Sulzfeld, Germany) and only 
male animals were included in the experiments, the different strains used in each study are 
summarized in Table 1. Every animal had at least 1 week resting period before the start of 
experiments to habituate to its new environment. Animals were housed in groups according 
to regulations at Karolinska Institutet in a thermoregulated (~ 22°C) and humidity-controlled 
facility under a 12 h/12 h light/dark cycle with access to food and water ad libitum. 
Table 1. The different mouse, rat and guinea pig strains used in this thesis work. 
 Mouse Rat Guinea pig 
Study I C57BL/6J Wistar - 
Study II C57BL/6J Wistar Dunkin Hartley 
Study III C57BL/6J Wistar - 
Study IV - Sprague-Dawley - 
Study V 
B6.D1-de10a<tm1Pfi>/J 
and C57BL/6J 
- - 
All animals in Study I, II and III were wild type animals. 
In study II supplement, we present results from multidrug resistance protein 1a (MDR1a) 
knockout rats. In rodents the Mdr1 gene has two subtypes Mdr1a, the equivalent of the 
human P-gp, and Mdr1b. Mdr1a is expressed mostly in the BBB, intestine and blood-testis 
barriers, while Mdr1b is found in brain parenchyma, kidney and liver. By specifically 
removing the function of Mdr1a (P-gp), it is possible to visualize the effect of P-gp on brain. 
In study IV we have used a surgically induced ischemic stroke model in Sprague-Dawley 
rats; these animals went through an occlusion of the M2-segment of the left middle cerebral 
artery (M2CAO) before imaging. 
3.1.1 Ethical approval 
All animal experiments were conducted according to the guidelines of the Swedish National 
Board of Laboratory under protocols approved by the Ethics Review Board of Northern 
Stockholm, Sweden (N210/10; N557/11; N253/12; N40/11).  
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3.2 RADIOCHEMISTRY 
The following radioligands have been used in this thesis: [11C]AZ10419369, [11C]PBR28, 
[11C]T-773, [11C]FLB 457. All of them were prepared at Karolinska Institutet with 
methylation of their respective desmethyl precursor using [11C] methyl triflate.  
Preparation of [11C]AZ10419369 was according to procedures described earlier in detail (95, 
96), while [11C]PBR28 was synthesized similarly to previously described methods with 
partial modifications (97). [11C]T-773 and [11C]FLB 457 was labelled by an O-methylation 
reaction according to previously reported methods (98, 99). In short, radioligand preparation 
was done by the following procedures: [11C]CH4 was released from the target and collected in 
a Porapak Q trap cooled with liquid nitrogen. Following the collection [11C]CH4 was released 
from the trap by heating with pressurized air and subsequently [11C]CH4 was mixed with 
vapours from iodine crystals at 60°C, directly followed by a radical reaction at 720°C. After 
the reaction, [11C]CH3I was collected in a Porapak Q trap at room temperature and the 
unreacted [11C]CH4 was recirculated for another 3 min. The Porapak Q trap was heated to 
180°C by a home-produced oven to release [11C]CH3I from the trap. [11C]methyl triflate was 
prepared by sweeping [11C]CH3I vapour through a heated glass column containing silver-
triflate-impregnated graphitized carbon. 
The radiosynthesis of each radioligand was obtained by trapping [11C]methyl triflate at room 
temperature in a reaction vessel containing the corresponding mixture of precursor, base and 
solvent. After the reaction, the respective mixture was diluted with HPLC eluent before being 
injected to the HPLC system to purify the product. Afterwards the ligands were formulated in 
10% EtOH/PBS mixture. 
3.3 EXPERIMENTAL DRUGS: 
3.3.1 Cyclosporin A 
Cyclosporin A (CsA) is an immunosuppressive drug used in organ transplantation. Due to its 
nonsteroidal nature it doesn’t have bone marrow suppression (myelotoxicity) which is a 
major advantage in clinical use (100). CsA inhibits promoters of T-cell activation to reduce 
immune response, inhibits lymphokine production and the release of interleukins leading to 
reduced T helper cell (adaptive immune system) activity (101). 
It has been found, that CsA uptake in the brain is restricted by P-glycoprotein (P-gp 
(ABCB1)) an efflux pump in the endothelial cells of the brain capillaries (102) and that CsA 
has the potential to enhance the accumulation of chemotherapeutic agents through the BBB 
into brain tissue (103). Therefore CsA has been recognized as an inhibitor of P-gp function 
and has been used as a P-gp blocker in PET experiments (104). Recently it has been 
recognized that CsA is not selective for P-gp but it has varying affinity for many transport 
proteins from the solute carrier family, such as other ABC transporters like mrp2 (ABCC2) 
and BCRP or different organic anion-transporting polypeptide (OATP) transporters as well 
(105–108). 
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In Study II 50 mg/ml CsA (formulated in 96% ethanol) was administered intravenously 15 
min before the injection of the radioligand. CsA was purchased from Novartis Sverige AB 
(Täby, Sweden). Due to the side effects of CsA (nephrotoxicity, neurotoxicity, hypertension 
etc.), the animals were terminated right after the experiments with CsA pretreatment. 
3.4 PHANTOMS USED FOR PHYSICAL VALIDATION 
3.4.1 PET 
For spatial resolution and sensitivity measurements, we used a 370 kBq 22Na point source 
(MMS09-022-10U; Eckert and Ziegler). The source is embedded into a 1 cm3 acrylic cube. 
Since iterative algorithms can overestimate the resolution of point sources in air (109), spatial 
resolution achievable in preclinical studies was evaluated using a micro-Derenzo phantom. 
Scatter fraction, count losses, and random coincidence measurements were performed with 
the mouselike (70 mm length, 25 mm diameter) and ratlike (150 mm length, 50 mm 
diameter) phantoms, consisting of a high-density polyethylene cylinder with an off-centred 
axial bore of 3.2 mm diameter for a plastic tube filled with 18F- ions in rinse water. 
For image quality, accuracy of attenuation, and scatter corrections we have used the NEMA 
NU 4 image quality phantom filled with [18F]FDG. 
3.4.2 MR 
To measure the signal-to-noise ratio and image uniformity we used a plastic sphere 46 mm in 
inner diameter and a cylinder 21 mm in inner diameter and 60 mm in length. Both phantoms 
were filled with the same solution of NiCl2, having T1 and T2 relaxation times of 129 and 125 
ms, respectively. 
For the 2D geometric distortion and geometric fidelity measurements the test object was a 
sphere of 46 mm inner diameter with a cube inside and filled with a dilute solution of NiCl2. 
3.5 IN VIVO PET EXPERIMENTS 
In all experiments with PET the animals were anaesthetized under isofluorane gas anaesthesia 
(induction: 4% - 5%, maintenance 1.5% - 2%) and placed into a heated imaging chamber 
with inbuilt temperature and breathing monitoring. The head was fixated through the mouth 
cone of the bed and the whole body of the animal was covered and taped to the imaging 
chamber for insulation and movement restriction during multimodal imaging. Before the PET 
experiments a cannula was inserted in the tail vein of the mice and rats, and in case of the 
guinea pigs in the tarsal vein for ligand injection. 
3.5.1 PET systems 
During this thesis work the Mediso nanoScan PET/MRI and nanoScan PET/CT small animal 
imaging systems were used (Fig. 5). Both systems are based on identical PET rings consisting 
12 detector modules of lutetium yttrium orthosilicate:cerium (LYSO:Ce) crystals and 2 
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multianode position-sensitive photomultipliers (H9500; Hamamatsu) per detector module 
(110). 
 
Figure 5. Mediso nanoScan PET/CT (on the left) and nanoScan PET/MRI (on the right) small animal imaging 
systems installed at KI PET Center. 
3.5.2 PET experimental procedures 
The animals were positioned in the PET camera in transaxial position with their heads in the 
center of the FOV. Before each injection, the radioligand was diluted in saline to reach 
around 60-100 MBq/ml solution in case of rats and guinea pigs and 100-150 MBq/ml in case 
of mice. The aimed volume of diluted radioligand for injection was 0.1 - 0.2 ml in mice and 
0.3 - 0.5 ml in rats and guinea pigs in line with the guidelines of bolus injection for small 
animals. The injected volume was adjusted based on the weight of the animal. The 
radioligand was intravenously administered simultaneously with the start of the PET 
acquisition and was followed by a 0.1 ml saline flush in mice and 0.2 ml in rats and guinea 
pigs. 
During the PET measurements radioactivity levels in the brain were measured continuously 
using the Mediso nanoScan PET/MRI and the nanoScan PET/CT small animal imaging 
systems in list mode. Two animals were examined at the same time in the identical PET 
modules of the two PET systems. The acquired data was later reconstructed into different 
timeframes depending on acquisition length. With 63 min long scans we have used 25 
timeframes (consisting 4x10 s, 4x20 s, 4x60 s, 7x180 s, 6x360 s frames) in case of mice and 
rats in Study I-V, while with 93 min long scans we have used a 35 timeframe setup 
(consisting 4x10 s, 4x20 s, 4x60 s, 7x180 s, 11x360 s frames) in case of guinea pigs in Study 
II. For reconstruction a fully 3-dimensional MLEM algorithm was applied with 20 iterations, 
without the use of scatter and attenuation correction. 
3.5.3 Radiometabolite determination in plasma 
In Study III we have used reversed-phase HPLC methods to evaluate metabolism of 
[11C]PBR28 in rats by determining the percentage of radioactivity in plasma that 
corresponded to the unchanged radioligand and its radioactive metabolites during our 
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experiments. During these experiments, four rats have been prepared with a second cannula 
in the femoral artery for blood sampling in addition to the cannula in their tail vein for 
radioligand injection. Sixteen arterial blood samples of 0.1 ml were taken for measurement of 
radioactivity in plasma and blood using a gamma counter and four samples of 0.5 ml blood 
were taken for radiometabolite analysis at 4, 20, 40 and 60 minutes after injection. 
For the metabolite analysis plasma was obtained by centrifugation of 0.5 ml blood at 2000 g 
for 2-4 min. The plasma was mixed with acetonitrile (0.35 ml) afterwards and centrifuged for 
another 4 min. The supernatant was mixed with 2 ml of water and injected to a HPLC system 
for analysis. Peaks for radioactive compounds eluting from the column were integrated and 
the unchanged radioligand was expressed as a percentage of the sum of the areas of all 
detected radioactive compounds (decay-corrected to the time of injection on the HPLC). 
3.5.4 Regions of interests and brain templates 
The reconstructed dynamic mouse and rat PET images in study I-V were co-registered to 
their respective MRI template available in PMOD incorporating volume of interest (VOI) sets 
as well (PMOD Technologies Ltd., Zurich, version: 3.3). Coregistration was done manually 
with the use of mean PET images focusing on early (flow phase) and late (binding phase) 
PET signals. In study II the guinea pig scans were coregistered to a template MRI with an in-
house developed VOI set using similar procedures as with mice and rats (Fig. 6). 
 
Figure 6. Mouse, rat and guinea pig regional VOIs overlaid on a sagittal section of their respective MRI 
template. 
With the help of these VOI sets, decay corrected time activity curves (TAC) were generated. 
Whole brain and regional brain uptake values were expressed as percent standard uptake 
value (%SUV), which was calculated by normalizing regional radioactivity for injected 
radioactivity and body weight (Fig. 7). 
  
Figure 7. Calculation of percent standard uptake value (%SUV). 
3.5.5 Quantitative PET data analysis 
In this thesis Logan Graphical Analysis and 2-TCM has been used to calculate VT of 
[11C]PBR28 (Study III) and SRTM modelling was used to estimate BPND of 
[11C]AZ10419369 (Study II) or [11C]T-773 (Study IV). 
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3.6 SURGICAL PROCEDURES - M2CAO 
The animals were placed into an interventional angiography system (Philips AlluraXper XD, 
Philips Medical Systems, Best, The Netherlands) and anaesthetized with inhalation of 
isoflurane (1.5% in oxygen) during surgery. A microwire (0.007F Hybrid Microwire; Balt 
Extrusion, Montmorency, France) sheeted within a microcatheter (1.5F hydrophilic 
Ultraflow; Covidien, Mansfield, MA, USA) was introduced through the ventral tail artery and 
the tip was navigated to the M2-segment of the left middle cerebral artery creating occlusion 
of the artery (M2CAO). After 90 minutes the microwire was removed (111). 
3.7 IMMUNOFLUORESCENCE STUDIES 
In Study IV, parallel to PET, immunofluorescence (IF) techniques were used to outline the 
cellular response to acute ischemic injury following M2CAO. 
After sacrificing the animals all brains were snap frozen and kept at -80°C until cryosectioned 
at 14 µm thickness. Samples were collected after 1, 2, 3, 4, 7, 14 and 22 days after 
reperfusion. The sections were triple stained with anti-Cd11b (marker for 
monocytes/macrophages and microglia), glial fibrillary acidic protein (GFAP, marking 
astrocytes and ependymal cells) and TSPO antibody according to a standard IF protocol and 
tyramide signal amplification (TSA) technique (112). On separate slices neuronal nuclei 
marker was used for lesion delineation, in combination with phagocyte marker anti-Cd68 in a 
double staining regime (113).  
Cd11b/GFAP/anti-TSPO Triple staining data set: Sections were scanned on a Vslide slide 
scanning microscope (Metasystems, Altlußheim, Germany) and the images were analysed in 
Metaviewer software (Metasystems). For confocal laser microscopy, images were captured 
on a Zeiss 710LSM laser-scanning microscope. Cells were registered as positive if meeting 
the following criteria: clear antibody immunoreactivity and positive for nuclear 
counterstaining. Weak or dispersed staining patterns were considered negative.  
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4 RESULTS AND DISCUSSION 
4.1 OVERVIEW 
This thesis focuses on advancements in the small animal imaging field with PET. Most of the 
obstacles in small animal imaging revolve around the subject’s relatively small size and the 
fact that some of the methodologies used routinely in human PET are not easily applied to 
rodents. The aim was to improve on several aspects of small animal imaging, starting with a 
development of a high resolution small animal PET system (Study I), to bring attention to the 
importance of species selection in PET translational research (Study II) and to overcome the 
obstacle of limited available blood volumes for metabolite analysis in longitudinal 
experiments (Study III). Finally said advancements have been applied during the validation of 
a neuroinflammation animal model (Study IV) and in the development of a new PET ligand 
(Study V). 
4.2 SECTION 1 - SCANNER PHYSICAL VALIDATION 
4.2.1 Study I: Validation of the nanoScan PET/MRI system 
The nanoScan PET/MRI is a high-resolution integrated system for consecutive PET and MR 
imaging of small laboratory animals. The imaging system uses magnetically shielded 
position-sensitive photomultiplier tubes together with a compact 1 Tesla permanent-magnet 
MRI. We evaluated the performance of the system, using different NEMA standards (PET: 
NEMA NU 4-2008; MRI: NEMA MS 1-2007, MS 2-2008 and MS 3-2007) to measure 
spatial resolution, sensitivity, counting rate capabilities, and image quality parameters. Finally 
we have complemented our test with several in vivo experiments to demonstrate the systems 
real-life performance. 
 
Figure 8. Image of a micro-Derenzo phantom filled with 9.34 MBq of [18F]FDG. Diameters of rods within the 
sections are 1.2, 1.1, 1.0, 0.9, 0.8 and 0.7 mm.  
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The spatial resolution of the PET system enabled the 0.8 mm rods of a Derenzo phantom to 
be resolved (Fig. 8). With point source and 2-dimensional filtered back-projection 
reconstruction, the resolution varied from 1.50 to 2.01 mm in full width at half maximum in 
the radial direction and from 1.32 to 1.65 mm in the tangential direction within the radius of 
25 mm. 
The performance characteristics of the PET system were comparable to the previous 
validation of nanoScan PET/CT (110), therefore the system proved to be not compromised as 
a result of their integration onto a single platform. During the testing of the MR imaging 
component, we have acquired artefact-free images with high signal-to-noise ratio (Fig. 9). 
Geometric distortion was below 5%, and image uniformity was at least 94.5% and 96.6% for 
the 60 and 35 mm radiofrequency coils, respectively.  
 
Figure 9. Three-dimensional MR brain scans: T2-weighted fast spin echo in rat, with scan time of 22:24 min 
(A); T2-weighted fast spin echo in mouse, with scan time of 20:00 min (B); and spoiled gradient echo in rat, 
with scan time of 14:13 min (C).  
Due to the combination of features and performance parameters in the nanoScan PET/MR 
imaging system, we now have the possibility to use a multimodal system, with anatomical 
information on soft tissue together with functional images from PET to improve our small 
animal imaging analysis. 
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4.3 SECTION 2 - METHODOLOGICAL CHALLENGES IN SMALL ANIMAL 
IMAGING 
4.3.1 Study II: Species differences in blood-brain barrier function 
The main objective of the present study was to explore the differences in BBB transport of 
[11C]AZ10419369, with special regard to the ABC transporter activities, in three rodent 
species: mouse, rat and guinea pig. PET measurements were performed after i.v. injection of 
[11C]AZ10419369 in the baseline conditions and after pretreatment with cyclosporin A 
(CsA), an inhibitor of ABC transporters. In the study we have imaged eight male C57BL/6J 
mice, seven male Wistar rats and seven male Dunkin Hartley guinea pigs under baseline 
conditions and, on separate experimental days, 15 min after administration of 50 mg/kg CsA. 
Uptake values (%SUV) were calculated as a summation of uptake from 10 min to the end of 
the PET acquisition and non-displaceable binding potential (BPND) was estimated using 
SRTM (13). 
During baseline conditions the brain uptake was low in mice and rats with fast clearance of 
[11C]AZ10419369, while there was a slow wash out in guinea pigs in both conditions (Fig. 
10). After CsA pretreatment the peak whole brain uptake values of [11C]AZ10419369 
increased by 207% in mice, 94% in rats and 157% in guinea pigs. The highest BPND values 
were obtained in the striatum and thalamus (BPND ≈ 0.4) in mice after CsA pretreatment, 
while in rats the highest binding areas were the striatum, thalamus, hypothalamus and 
periaqueductal grey (BPND ≈ 0.5). In guinea pigs we did not find any significant changes in 
BPND between baseline and CsA pretreatment, except in the striatum, which was probably 
due to the remarkably slow wash out. In most of the guinea pig measurements neither of the 
regions could reach equilibrium despite the 2 hour long scanning time, which makes the 
SRTM calculations unreliable. 
The difference in kinetics and BPND observed in guinea pigs, compared with mice and rats, is 
most likely due to the differences in homology of the 5-HT1B receptor and the affinity of 
[11C]AZ10419369 to the 5-HT1B receptor. A previous report indicated that amino acid residue 
335 in the 5-HT1B receptor is a major determinant of its reactivity with several ligands (114). 
It has also been shown that AZ10419369 binds to human (Ki = 0.8 nM) and guinea pig (Ki = 
0.01 nM) 5-HT1B receptors with higher affinity than it does to rat 5-HT1B receptors (Ki = 2.3 
nM) (95). 
These results indicate that BBB penetration of [11C]AZ10419369 was hindered by ABC 
transporter activity in all three species, which highlights the importance of ABC transporters 
in the design of pre-clinical PET studies and during evaluation of results in translational 
research. 
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Figure 10. Representative %SUV uptake images from 10 min until the end of the scan (total 53 min in case of 
rat and mice, 113 min in case of guinea pig) on the left, while time activity curves of striatal and cerebellar 
uptake are presented on the right as mean values and SD as error bars, in mouse (n = 8), rat (n = 7) and guinea 
pig (n = 7) in baseline and pretreatment condition. 
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4.3.2 Study III: Validation of %SUV as an outcome measure for [11C]PBR28 
imaging in rodents 
Quantification of radioligands without a reference region in rodents, especially in mice, is 
quite difficult. The small amount of blood in rodents challenges our techniques for blood 
sampling, while in longitudinal studies the use of plasma-derived input for quantitative 
measurements seems impossible. Molecular imaging of TSPO, a marker for 
neuroinflammation, with [11C]PBR28 holds these difficulties, due to the absence of a 
standard reference region in the brain. The aim of this study was therefore to evaluate the use 
of the standardized uptake value (SUV) as an outcome measure for TSPO imaging with 
[11C]PBR28.  
To achieve this we have used four healthy male Wistar rats to determine the correlation 
between the VT and SUV. In a separate group of four healthy male Wistar rats and four 
healthy male C57BL/6J mice we have determined the test-retest variability of the SUV (Fig. 
11). 
 
Figure 11. Sagittal test-retest PET images of a representative mouse and rat experiment are shown overlaying 
the individual MRI measurements. 
The whole brain VT of [
11C]PBR28 in rats was 43.1 (Logan) and 47.3 (2-TCM), with a very 
high correlation of VT values obtained from 2-TCM and Logan analysis for the eight different 
brain regions. There was a statistically significant correlation (r2 = 0.94; p < 0.001 with 
Logan; r2 = 0.92; p < 0.001 with 2-TCM) between the VT and the SUV of 8 brain regions 
(Fig. 12).  
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Figure 12. Correlation between VT of [11C]PBR28 as calculated using two-tissue compartment modelling (2-
TCM) (A+B) and Logan graphical analysis (C+D), and the SUV of [11C]PBR28, for the averages of eight brain 
regions (A+C) and for the individual values for each rats for the eight brain regions (B+D).  
The test-retest variability of SUV in 8 brain region ranged from 8% to 20% in rats and from 
7% to 24% in mice (Table 2).  
Table 2. Test-retest variability (TRV) of [11C]PBR28 for rats and mice. 
 
TRV in rats TRV in mice 
Striatum 13.6 ± 4.8 23.6 ± 15.6 
Hippocampus 7.7 ± 3.5 6.9 ± 4.7 
Hypothalamus 20.4 ± 15.4 23.0 ± 17.6 
Midbrain 12.3 ± 15.8 15.1 ± 6.3 
Thalamus 13.7 ± 9.2 7.6 ± 4.6 
Cerebral cortex 16.7 ± 9.2 13.4 ± 11.6 
Brainstem 17.7 ± 7.8 13.2 ± 9.1 
Cerebellum 11.5 ± 7.4 13.7 ± 6.4 
Validation of SUV as an outcome measure for [11C]PBR28 imaging in rodents was an 
important step in order to show that SUV can be used as an outcome measure in subsequent 
longitudinal small animal PET studies. 
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4.4 SECTION 3 - APPLICATION OF ANIMAL MODELS 
4.4.1 Study IV: Validation of a neuroinflammation animal model 
Adequate estimation of neuroinflammatory processes following ischemic stroke is essential 
for our better understanding of disease mechanisms and for the development of treatment 
strategies. With [11C]PBR28, we monitored longitudinally the inflammatory response post 
transient cerebral ischemia in rats, using a recently developed rat stroke model that produces 
isolated focal cortical infarcts with clinical relevance in size and pathophysiology. Six 
Sprague-Dawley rats went through a 90 min transient endovascular occlusion of the M2 
segment of the middle cerebral artery (M2CAO). Animals were imaged with 1, 4, 7 and 14 
days after M2CAO with a bolus injection of [11C]PBR28. 
In the infarct region we found a significantly increased uptake of [11C]PBR28 on day 4, 7 and 
14 compared to day 1 as well as compared to the contralateral cortex (Fig. 13). No significant 
difference was detected in the contralateral cortex during the 14 days of imaging. The 
activation in the infarct region gradually decreased between day 4 and day 14. 
 
Figure 13. (A) Average time activity curves of infarct areas on day 1(n = 6), day 4 (n = 6), day 7 (n = 6) and day 
14 (n = 5) and contralateral cortical areas from all imaging days (n = 23). (B) %SUV values of [11C]PBR28 
uptake in the Infarct and the Contralateral Cortex region on day 1 (n = 6), day 4 (n = 6), day 7 (n = 6) and day14 
(n = 5) (* = p < 0.05). 
In an additional group of animals (n = 26), immunofluorescence studies were performed with 
antibodies for activated microglia/macrophages (Cd11b, Cd68), astrocytes (GFAP) and 
TSPO. The TSPO immunofluorescence signal indicated reactive microgliosis post injury, 
corresponding to the PET findings. 
Based on the findings the present M2CAO animal model together with [11C]PBR28 appears 
to be well suited for studies on neuroinflammation after ischemic stroke. 
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4.4.2 Study V: Molecular imaging of PDE10A - Radioligand validation in 
knockout mice 
The development of PDE10A-selective PET radioligands is of high importance as they can 
serve as molecular imaging biomarkers in the development of therapeutic drugs, help during 
the diagnosis of different neurological or psychiatric diseases such as HD, and also allow for 
monitoring the therapeutic effect of drugs in HD patients. Knockout animals offer an 
excellent advantage for radioligand development due to their added value of dissecting the 
specific signal from non-specific sources. In this study we have evaluated the newly 
developed radioligand [11C]T-773 in PDE10A knockout mice (heterozygous[HET] and 
homozygous [HOM] B6.D1-Pde10a<tm1Pfi>/J) and used wild type animals (WILD, 
C57BL/6J) as controls. 
[11C]T-773 showed accumulation in the striatum over time, whereas in other brain regions 
examined (i.e., cerebellum and cortex), there was a clear rapid washout. There was an 
acceptable uptake in the striatum of WILD mice, moderate uptake in HET mice, and low 
uptake in HOM mice (Fig. 14). 
 
Figure 14. Representative images of [11C]T-773 uptake (summation of 15-63 min) in homozygous (HOM), 
heterozygous (HET) and wild-type (WILD) mice (from left to right) overlayed on mice template MRI (left). 
Based on %SUV values (15-63 min) the uptake of radioligand in the striatum of HOM mice 
was 44% lower while 25% lower in HET mice compared to WILD mice. Between each 
animal group the striatal %SUV values were significantly different (p < 0.0001) and the BPND 
values were significantly lower in homozygous and heterozygous animals compared to 
WILD (p < 0.0001) (Fig. 15). 
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Figure 15. Comparison of %SUV in Striatum, Cortex and Cerebellum (a) and BPND in Striatum and Cortex (b). 
Values are means ± SD. 
The significant reduction of binding in the striatum in PDE10A knockout mice confirms that 
[11C]T-773 binds selectively to PDE10A, and the clear regional distribution of uptake 
strengthens the suitability of [11C]T-773 as a radioligand for imaging PDE10A.
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5 CONCLUSIONS 
The findings of the present thesis, focusing on methodological advancements in the small 
animal PET imaging field, are summarized below. 
5.1 SECTION 1 
 Combination of a 1 Tesla standard MRI magnet with the PET ring of the nanoScan 
PET/CT system did not affect the performance of the final nanoScan PET/MRI 
system. Together with the integrated MRI component the system is capable of 
conducting consecutive multimodal imaging with functional images from PET and 
provides anatomical information on soft tissue while keeping the subject animal in the 
same position. Indicating that combined PET-MRI systems have a great advantage in 
pre-clinical imaging, due to their improved work-flow performance as compared to 
that of stand-alone systems. 
5.2 SECTION 2 
 ABC transporter activity in translational research should be taken into account as the 
BBB penetration of [11C]AZ10419369 was completely blocked in mouse and rat 
while only reduced in guinea pig. This highlights the necessity of proper animal 
model selection while designing pre-clinical PET studies. 
 SUV can be used as an outcome measure for [11C]PBR28 imaging in rodents in 
longitudinal small animal PET studies, as the validation of [11C]PBR28 test-retest in 
healthy mice and rats showed good results and there was a statistically significant 
correlation between VT and SUV of [
11C]PBR28 in rats. 
5.3 SECTION 3 
 The M2CAO stroke rat model showed significantly up-regulated TSPO signal, 
measured with [11C]PBR28, in the infarct region. There was a decrease of said 
activation from day 4. showing that the present M2CAO model is well suited for 
studies on neuroinflammation with a more rapid response compared to the previous 
MCAO model. 
 The significant reduction of binding in the striatum in PDE10A knockout mice 
confirms that [11C]T-773 binds selectively to PDE10A, and the clear regional 
distribution of uptake strengthens the suitability of the ligand. 
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6 FUTURE PERSPECTIVES 
 
Improvements on MRI based attenuation maps 
One limitation of combined PET/MRI imaging compared to PET/CT systems is the lack of 
readily available attenuation maps. Even though this is less of an issue in small animal brain 
imaging, where the head is not subject to movement and the thin skull of rodents is equally 
distributed around the brain, other research areas like lung or hearth imaging could greatly 
benefit from the same level of attenuation and scatter correction as in PET/CT systems. 
Image derived input function 
Even though SUV has proven to be applicable for [11C]PBR28 uptake estimation in rodents, 
for other radioligands without reference region in the brain the same might not be possible. 
Small animal imaging has the possibility of simultaneous brain and hearth imaging due to the 
large FOV compared to the body size of some rodent species. This has the possibility to 
facilitate the application of image derived input function methods similar to the 
advancements in human research (115), but with the use of the left ventricle instead. 
New neuroinflammation marker 
As the current neuroinflammation markers are targeting the TSPO in mitochondria, its uptake 
during imaging can originate from multiple sources. Separation of monocyte, astrocyte and 
microglial signal, by specific markers for the different cells involved is high priority for 
future ligand development. New targets for neuroinflammation imaging other than TSPO are 
a necessity in the future. The research related to the P2X7 receptor might provide a new and 
interesting path for the development of novel radioligands, in which the M2CAO model 
validated in study IV could prove to be beneficial. 
Future of knock-out animals in PET 
At present the most widely used animal species for producing gene knockout animals is the 
mouse. Its advantage over other rodent species is obvious with faster reproduction and 
smaller required space, but in PET imaging their small brain size and consequently smaller 
brain structures provide a disadvantage as an animal model for neuroscience. A normal 
mouse has a cortical thickness of 1.2 mm while larger sized rodents like rats show a cortical 
thickness of 1.8 mm (24). While the mouse cortex is possibly still effected by partial volume 
effect even with the currently achieved advancements of under mm resolutions, larger rodent 
brains like rat or guinea pig is more likely to be devoid of measurement errors originating 
from small brain regions. Thus development of small animal knockouts other than mouse is 
advantageous for the future of functional in vivo PET imaging.   
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